Brief: FDA Identifies Bausch + Lomb/Synergetics Inc's Certain I-Pack Injection Kits Recall As Most Serious Type
July 15 (Reuters) - Bausch + Lomb Corp BLCO.TO :
* FDA: BAUSCH + LOMB/SYNERGETICS INC. REMOVES CERTAIN I-PACK
INJECTION KITS DUE TO POTENTIAL NON-STERILITY
* FDA: IDENTIFIED BAUSCH + LOMB/SYNERGETICS INC.'S CERTAIN
I-PACK
INJECTION KITS RECALL AS MOST SERIOUS TYPE
Source text for Eikon: ID:
Further company coverage: BLCO.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bausch + Lomb
See all newsBausch + Lomb CEO Saunders departs, Chairman Appio named interim chief (updated)
Brief: Bausch + Lomb And Bausch Health Announce Appointment Of Thomas J. Appio As Interim Bausch + Lomb CEO, Expect To Raise Full-Year 2026 Guidance
Bausch + Lomb CEO Saunders steps down, Chairman Appio appointed interim chief
Brief: US FDA sent warning letter to Bausch & Lomb on September 4
Brief: Bausch + Lomb Announces European CE Mark Approval Of Seelyra™ Femtosecond Laser